Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).
from News-Medical.Net Mesothelioma News Feed http://www.news-medical.net/news/20151119/Lilly-Merck-expand-oncology-clinical-trial-collaboration.aspx
Lilly, Merck expand oncology clinical trial collaboration
ad
Enregistrer un commentaire